A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer
Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Here, we developed a targeted nanoplatform based on biodegradable boronic acid modified ε-polylysine to co-deliver P-gp siRNA, Bcl-2 siRNA, and doxorubicin for overcoming the challenge. The targeted nanoplatform showed a robust suppressing efficiency for the invasion, proliferation, and colony formation of adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) cells in vitro. The ATP responsiveness of the nanoplatform was also proved in the research. In the in vivo antitumor experiment, the targeted nanoplatform showed a significant inhibition of tumor growth with good biocompatibility. The goal of this study is to develop a novel and facile strategy to prepare a highly efficient and safe gene and drug delivery system for MDR breast cancer based on biocompatible ε-polylysine polymers..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nano research - 15(2022), 7 vom: 18. Apr., Seite 6306-6314 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Hongmei [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
50.94 / Mikrosystemtechnik / Nanotechnologie / Mikrosystemtechnik / Nanotechnologie |
|---|---|
| Themen: |
ε-polylysine |
| Anmerkungen: |
© Tsinghua University Press 2022 |
|---|
| doi: |
10.1007/s12274-022-4254-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2131267169 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2131267169 | ||
| 003 | DE-627 | ||
| 005 | 20240325182633.0 | ||
| 007 | tu | ||
| 008 | 230506s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12274-022-4254-1 |2 doi | |
| 035 | |a (DE-627)OLC2131267169 | ||
| 035 | |a (DE-He213)s12274-022-4254-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 500 |q VZ |
| 084 | |a 50.94 |2 bkl | ||
| 100 | 1 | |a Liu, Hongmei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Tsinghua University Press 2022 | ||
| 520 | |a Abstract Multi-drug resistance (MDR) has become the largest obstacle to the success of cancer patients receiving traditional chemotherapeutics or novel targeted drugs. Here, we developed a targeted nanoplatform based on biodegradable boronic acid modified ε-polylysine to co-deliver P-gp siRNA, Bcl-2 siRNA, and doxorubicin for overcoming the challenge. The targeted nanoplatform showed a robust suppressing efficiency for the invasion, proliferation, and colony formation of adriamycin (ADR) resistant breast cancer cell line (MCF-7/ADR) cells in vitro. The ATP responsiveness of the nanoplatform was also proved in the research. In the in vivo antitumor experiment, the targeted nanoplatform showed a significant inhibition of tumor growth with good biocompatibility. The goal of this study is to develop a novel and facile strategy to prepare a highly efficient and safe gene and drug delivery system for MDR breast cancer based on biocompatible ε-polylysine polymers. | ||
| 650 | 4 | |a multi-drug resistance (MDR) | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a adenosine triphosphate (ATP) responsiveness | |
| 650 | 4 | |a ε-polylysine | |
| 700 | 1 | |a Ma, Ding |4 aut | |
| 700 | 1 | |a Chen, Jinpeng |4 aut | |
| 700 | 1 | |a Ye, Li |4 aut | |
| 700 | 1 | |a Li, Yiping |4 aut | |
| 700 | 1 | |a Xie, Yuexia |4 aut | |
| 700 | 1 | |a Zhao, Xue |4 aut | |
| 700 | 1 | |a Zou, Hanbing |4 aut | |
| 700 | 1 | |a Chen, Xiaojing |4 aut | |
| 700 | 1 | |a Pu, Jun |4 aut | |
| 700 | 1 | |a Liu, Peifeng |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nano research |d Tsinghua University Press, 2008 |g 15(2022), 7 vom: 18. Apr., Seite 6306-6314 |w (DE-627)57478733X |w (DE-600)2445065-0 |w (DE-576)443179816 |x 1998-0124 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:7 |g day:18 |g month:04 |g pages:6306-6314 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12274-022-4254-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 50.94 |j Mikrosystemtechnik |j Nanotechnologie |j Mikrosystemtechnik |j Nanotechnologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 7 |b 18 |c 04 |h 6306-6314 | ||